Nomura Holdings Inc. Purchases New Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Nomura Holdings Inc. acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, Holdings Channel reports. The fund acquired 3,382 shares of the company’s stock, valued at approximately $1,124,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. R Squared Ltd purchased a new stake in Medpace in the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new position in Medpace during the fourth quarter worth $31,000. Jones Financial Companies Lllp raised its position in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the period. Finally, Assetmark Inc. boosted its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after purchasing an additional 29 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

Medpace stock opened at $305.66 on Monday. The stock has a market capitalization of $8.79 billion, a P/E ratio of 24.20, a P/E/G ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The firm’s 50-day moving average is $304.24 and its two-hundred day moving average is $327.86.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter last year, the business earned $3.20 earnings per share. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Robert W. Baird cut their price target on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating for the company in a report on Wednesday, April 23rd. William Blair reissued a “market perform” rating on shares of Medpace in a research note on Tuesday, April 22nd. Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday, March 24th. TD Cowen downgraded Medpace from a “buy” rating to a “hold” rating and decreased their target price for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Truist Financial dropped their price target on Medpace from $333.00 to $300.00 and set a “hold” rating for the company in a research report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $349.30.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now owns 2,998 shares of the company’s stock, valued at $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.